This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Zacks.com featured highlights include: Macy's, Adient, Imperial Oil, Ryder System and The Chemours Co
by Zacks Equity Research
Zacks.com featured highlights include: Macy's, Adient, Imperial Oil, Ryder System and The Chemours Co
5 Top-Ranked Stocks Displaying High Earnings Yield
by Rimmi Singhi
Earnings yield is an important tool for investors with exposure to both stocks and bonds.
Why You Should Add Chemours (CC) Stock to Your Portfolio Now
by Zacks Equity Research
Chemours (CC) benefits from increasing adoption of the Opteon platform and its efforts to reduce costs.
CC or PPG: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
CC vs. PPG: Which Stock Is the Better Value Option?
Are Investors Undervaluing Chemours (CC) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is Chemours (CC) Stock a Solid Choice Right Now?
by Zacks Equity Research
Chemours (CC) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Strong Demand, Manufacturing Upswing Buoy Chemicals: 5 Top Picks
by Anindya Barman
A strong revival in industrial demand and strengthening manufacturing activities are driving the upturn in the chemical industry. DOW, OLN, UNVR, WLK and CC are good options for investment right now.
Chemours (CC) Stock Hits 52-Week High: What's Driving It?
by Zacks Equity Research
Chemours (CC) is gaining from higher demand for Opteon in mobile applications and cost-cutting measures.
Why Is Chemours (CC) Up 18.5% Since Last Earnings Report?
by Zacks Equity Research
Chemours (CC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Chemours' (CC) Opteon XL41 Selected by Johnson Controls
by Zacks Equity Research
Chemours (CC) has been selected by Johnson Controls to provide Opteon XL41 for the latter's HVAC products to facilitate the phase out of high GWP options.
Is Chemours (CC) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Chemours (CC) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Chemours (CC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Here's Why Chemours (CC) is a Great Momentum Stock to Buy
by Zacks Equity Research
Does Chemours (CC) have what it takes to be a top stock pick for momentum investors? Let's find out.
Book Profits by Investing in These High Earnings Yield Picks
by Rimmi Singhi
Invest in high earnings yield stocks like PBR, HIMX, TEN and CC for sturdy gains.
Should Value Investors Buy Chemours (CC) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Chemours (CC) Earnings and Revenues Beat Estimates in Q1
by Zacks Equity Research
Chemours' (CC) Q1 results benefit from higher sales in Titanium Technologies and Advanced Performance Materials units driven by demand recovery.
Chemours (CC) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Chemours (CC) delivered earnings and revenue surprises of 4.41% and 3.80%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Central Banks Start to Care About Fundamentals?
by John Blank
Macro-data has been much stronger than expected.¿¿¿¿¿¿ Still, the only thing that matters is NOT whether stock traders (or pundits) take note of strong data. It is whether the Fed and other major central banks care.
Chemours (CC) Starts Strategic Review of Mining Solutions Unit
by Zacks Equity Research
Chemours' (CC) overall goal is to position each of its businesses, including Mining Solutions, to deliver the highest level of profitable growth.
3 Reasons Why Growth Investors Shouldn't Overlook Chemours (CC)
by Zacks Equity Research
Chemours (CC) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Chemours (CC) Tops Earnings and Revenue Estimates in Q4
by Zacks Equity Research
Chemours' (CC) fourth-quarter performance benefits from a global macroeconomic recovery.
Is Chemours (CC) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Chemours (CC) to Post Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Chemours' (CC) fourth-quarter 2020 results are likely to reflect recovery in demand across all markets and regions as well as benefits from cost-cutting measures.
Is The Chemours (CC) Stock Outpacing Its Basic Materials Peers This Year?
by Zacks Equity Research
Is (CC) Outperforming Other Basic Materials Stocks This Year?
New Strong Buy Stocks for January 28th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today: